Edit the message. Rewrite the future.

Editing a single letter on RNA to modulate a biological pathway. Our mission is to deliver the promise of genetic medicines to complex prevalent diseases.

home_hero

Supporting patients with alpha-1

People with AATD have clinical manifestations within the liver and lung organs. AATD is an inherited genetic disorder caused by a single letter change in a gene called SERPINA1. Our approach holds the potential of providing clinical benefits implicated in this disease.

Learn more about AATD

Our science

Our approach to edit RNA involves redirecting a naturally occurring editing process that’s inside every cell in the human body. This is accomplished by delivering a chemically modified RNA that helps to target precisely the change we want to make. Our proprietary platform called Oligonucleotide Promoted Editing of RNA (OPERA®) enables us to discover and develop these drug candidates.

See our science

Our pipeline

Our pipeline programs demonstrate the versatility of our approach in bringing precision and tunability to genetic medicines to address a broad range of rare and highly prevalent diseases. We can repair proteins caused by genetic mutations or alter proteins to activate a biological pathway.

View our pipeline

News and media

Career opportunities

Write the next chapter of your career with Korro, where we are developing a novel class of medicines.

See our opportunities